You are here: Industry Insights > NASH

News List

ContraVir Pharmaceuticals Submits IND for NASH Drug contractpharma
June 28, 2019
IND positions NASH as a second indication for CRV431, in addition to HBV.
CymaBay Therapeutics Reports Results for Seladelpar in NASH contractpharma
June 21, 2019
Results included minimal reductions in liver fat that were not significant when compared to placebo.
Terns Pharmaceuticals Initiates Phase 1 Clinical Trial of TERN-101 americanpharmaceuticalreview
June 14, 2019
Terns Pharmaceuticals announced the initiation of a Phase 1 clinical trial of TERN-101, a farnesoid X receptor (FXR) agonist, being developed for the treatment of non-alcoholic steatohepatitis (NASH).
Akero Therapeutics Initiates AKR-001 Phase 2a Clinical Trial for NASH americanpharmaceuticalreview
May 30, 2019
Akero Therapeutics announced it has screened the first patient for its Phase 2a clinical trial evaluating AKR-001, the company's lead product candidate for the treatment of NASH.
Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH) drugs
May 09, 2019
Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH).
Gilead’s selonsertib flunks another NASH phase 3 fiercebiotech
April 28, 2019
Gilead’s NASH candidate selonsertib has disappointed in yet another phase 3 trial. This time, two different doses of the drug did worse than placebo at reducing scarring in patients with bridging fibrosis—also called stage 3 fibrosis—from nonalcoholic ste
Gilead and insitro Ink Drug Discovery Deal April 24, 2019
Gilead Sciences and insitro have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH).
Gilead and insitro team up to develop treatment for NASH pharmaceutical-technology
April 18, 2019
Gilead Sciences has partnered with insitro, a data-driven drug discovery startup, to leverage an artificial intelligence (AI)-based platform for the discovery and development of new drugs to treat nonalcoholic steatohepatitis (NASH).
Stealthy Insitro opens up—starting with Gilead deal worth up to $1.05B fiercebiotech
April 17, 2019
Daphne Koller’s Insitro launched last May with a blog post detailing an ambitious goal: to harness data and machine learning in the creation of a new approach to drug discovery.
Gilead announces Novo Nordisk NASH partnership after new data revealed pharmatimes
April 16, 2019
Gilead Sciences has announced its intent to initiate a clinical collaboration with Novo Nordisk for a trial ……

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page